Summary

  • Select Medical’s definitive proxy disclosed 14,335,221 shares already committed to rollover before the vote, reducing the required cash merger consideration by approximately US$236.5 million.
  • On 26 June, more than 79.88% of all outstanding shares and more than 76.64% of unaffiliated shares approved the merger. Approval fixed the transaction path but did not identify the later additional participants.
  • After the vote and Special Committee approval, 53 additional investors signed a 30 June agreement covering 3,844,152 unrestricted shares. The schedule includes managers, directors, trusts and family accounts, not one uniform class of executives.
  • At US$16.50 a share, that later schedule maps arithmetically to US$63,428,508 of cash not taken. It is not a valuation of the private Class A units received in exchange.
  • Eligible non-rollover shares converted into cash, while rollover holders accepted unregistered private interests with no anticipated public market. At closing, Select Medical Corporation also became borrower under a new US$1 billion incremental term loan.
  • The closing disclosures report approximately US$1.7 billion of aggregate cash purchase price and majority economic ownership for the consortium, but not a complete final ownership table or a complete sources-and-uses reconciliation.

A merger vote can settle whether a company will be sold without settling which individual shares will be cashed out. Select Medical Holdings Corporation provides an unusually clean illustration because its filings record the two decisions on opposite sides of the vote.

The definitive proxy set the principal bargain. Eligible shares outside the rollover and other excluded categories would convert into US$16.50 in cash, without interest, when the merger became effective. It also disclosed 14,335,221 shares already committed to rollover. At the cash price, those commitments removed approximately US$236.5 million from the cash requirement. Exact multiplication gives US$236,531,146.50; the proxy used the rounded figure.

The same document left an authorized opening. With prior written approval from the Special Committee, other members of management and the board, excluding Special Committee members, could be invited to roll shares. The proxy explained the financing consequence: extra rollover could reduce the WCAS equity contribution or closing debt. This was not an automatic election available to every stockholder. It was a controlled admission route whose use would change the financing perimeter.

The vote approved a transaction, not a final participant list

At the 26 June special meeting, approximately 82.54% of outstanding shares were voted. The vote Form 8-K reports support from more than 79.88% of all outstanding shares and more than 76.64% of shares held by holders unaffiliated with the consortium. Those are strong approval receipts. They do not, however, name the investors who would enter the rollover after the meeting.

The chronology matters. The final Schedule 13E-3 says that after the special meeting approved the proposal, and after Special Committee approval, certain shareholders including management and board members were invited to participate. Parent, Group Parent and the additional investors executed the Additional Rollover Agreement on 30 June.

Schedule I makes the enlargement countable: 53 listed investors and 3,844,152 unrestricted shares. The names and account descriptions show a mixed population—individual managers and directors appear alongside trusts and family accounts. Calling all 53 executives would turn a schedule into a category it does not support.

The narrow conclusion is more useful. When stockholders voted, they had disclosure that additional approved rollover was possible and could change funding needs. They did not yet have the later Schedule I identifying the 53 participants and their precise unrestricted-share contributions. Approval and final selection were sequential corporate acts.

US$63.43 million describes the cash boundary only

Multiplying 3,844,152 by US$16.50 produces US$63,428,508. That figure answers one question: how much cash merger consideration those scheduled unrestricted shares would have received had they remained in the eligible cash perimeter. The agreement says the investors waived that cash treatment, contributed the shares into the parent chain and received Class A units in the private parent structure.

The calculation does not price those units. The consideration changed form, liquidity, governance setting and risk. The agreement says no public market for the exchange interests is anticipated in the foreseeable future. Participants represent that they can hold the interests indefinitely and bear a complete loss, and that they meet the relevant accredited-investor conditions. They also acknowledge that consolidated indebtedness after closing may be significantly greater than before it.

Those provisions make a US$16.50 mark-to-private-equity shortcut particularly misleading. A public cash entitlement is fixed and payable at closing. An unregistered private unit has no disclosed trading price, no promised exit date and no independently stated fair value in the cited receipts. US$63.43 million is therefore a counterfactual cash amount, not an assertion that the units were worth exactly that amount on 30 June.

The same restraint applies to total rollover. The pre-vote proxy’s 14,335,221-share commitment and the later schedule’s 3,844,152 unrestricted shares arise from different disclosure moments and categories. Restricted shares and amended agreements prevent a simple addition from proving the definitive final rollover balance. The documents establish a later expansion; they do not license a manufactured total.

Closing created three ledgers, not one deal-value number

The closing Form 8-K records the legal sorting. Eligible non-rollover shares became US$16.50 cash claims. Rollover shares had first been contributed into the parent structure and were cancelled in the merger without a second cash payment. The filing reports approximately US$1.7 billion as the aggregate cash purchase price for outstanding shares within the cash perimeter.

At the same closing, Select Medical Holdings Corporation and Select Medical Corporation entered Amendment No. 12. It established a US$1 billion incremental term loan under the existing credit agreement. The operating company is therefore where the new borrowing receipt appears, while the private-parent units sit with rollover investors and the cash consideration went to eligible sellers.

These are related financing choices, but they are not interchangeable numerators. The proxy had estimated approximately US$1.8945 billion of closing cash need, including consideration, fees and expenses; WCAS had committed up to US$880 million of equity and debt parties up to US$1 billion. The company also had an existing term-loan facility, revolver and senior notes expected to remain. Facility labels, headline company value, cash purchase price, rolled equity and new debt measure different things. Adding them produces noise rather than a capital structure.

The useful table would keep at least three columns: cash paid to eligible non-rollover shares; private equity issued for rollover contributions; and debt borrowed by the company. The public filings do not supply a complete dollar-by-dollar closing sources-and-uses schedule. Any exact allocation of the incremental loan among purchase consideration, fees, refinancing or other uses would go beyond the record.

Control survived; public visibility did not

The filed closing release says the consortium retained effective and operational control and held a majority of the post-closing economic interest. Current officers including Robert A. Ortenzio and Martin F. Jackson continued to lead the business. Those statements show continuity of command, but they do not provide a holder-by-holder cap table or an exact percentage for each sponsor and rollover group.

That missing table will be harder to reconstruct once a listed company becomes private. Public trading ended, and the company moved toward deregistration. The fixed cash price remains observable because it governed the public exit. Future transfers of private units, changes in sponsor ownership, internal distributions and leverage movements may not produce the recurring public filings that existed before closing.

The analytical edge is therefore temporal. Before the vote, investors could see the authorized mechanism and an initial rollover amount. After the vote, a new schedule identified another selected group. At closing, the company recorded new debt and the public equity disappeared. Anyone compressing those stages into a single “US$3.9 billion transaction” headline loses the two decisions that mattered most: who was allowed to remain invested and where the financing obligation landed.

Sources